Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epigenomics in cancer deal with Biogen Idec:

This article was originally published in Clinica

Executive Summary

German firm Epigenomics has entered into a research collaboration with pharmaceutical company Biogen Idec, to identify cancer-specific biomarkers using its proprietary DNA methylation technology. If the programme is successful, Epigenomics may exercise its option to develop a future pharmadiagnostic product with the drug developer. DNA methylation is a naturally occurring "switch" that controls the activity and expression of genes, including those for cancer. Changes in the patterns of DNA methylation can help identify those individuals most at risk of developing cancer and help assess their suitability for drug therapy. Pharmaceutical giants AstraZeneca and Wyeth have already secured similar agreements with Epigenomics, using their own anti-cancer therapies (Clinica No 1088, p 18).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel